Drug Safety Communication: DPP-4 inhibitors for Type 2-Diabetes may cause severe joint pain
Last Updated on August 29, 2015 by Joseph Gut – thasso
August 29, 2015 – This may after all not be so good news for Type 2-Diabetes patients on DPP-4 inhibitor medications. The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines containing the pharmacologically active ingredients (PAI) sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. The Table 1 below lists the currently FDA-approved medications containing one of these PAI alone or in combination with other anti-diabetes medications.
Table 1 – List of FDA-approved DPP-4 inhibitors
|Brand name||Active ingredient(s)|
|Janumet||sitagliptin and metformin|
|Janumet XR||sitagliptin and metformin extended release|
|Kombiglyze XR||saxagliptin and metformin extended release|
|Glyxambi||linagliptin and empagliflozin|
|Jentadueto||linagliptin and metformin|
|Kazano||alogliptin and metformin|
|Oseni||alogliptin and pioglitazone|
DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. See the complete Drug Safety Communication here for additional information on DPP-4 inhibitors and their use in the therapy of Type 2-Diabetes.
Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right away if they experience severe and persistent joint pain. Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if appropriate. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program online at: www.fda.gov/MedWatch/report
It might be worthwhile to also mention here that same of these medication come with a BOXED WARNING on Lactic Acidosis as well. And in addition, patients worldwide are likely being affected by the severe adverse effects addressed in this communication. Since there is a possibility that the brand names of DPP-4 inhibitor-containing medicines are not the same as in the US, patients are surely advised to do some research as to which PAI is present in the medication they take for Type 2-Diabetes treatment.
June 1...June 13, 2019
Ma...May 20, 2016
Midway...June 24, 2018
May 01...May 1, 2016
May 30...May 31, 2016